Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Adaptive Biotechnologies Q1 2024 GAAP EPS $(0.33) Beats $(0.35) Estimate, Sales $41.873M Beat $38.784M Estimate

Author: Benzinga Newsdesk | May 07, 2024 04:37pm
Adaptive Biotechnologies (NASDAQ:ADPT) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.35) by 5.71 percent. This is a 17.5 percent increase over losses of $(0.40) per share from the same period last year. The company reported quarterly sales of $41.873 million which beat the analyst consensus estimate of $38.784 million by 7.96 percent. This is a 11.23 percent increase over sales of $37.647 million the same period last year.

Posted In: ADPT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist